Real-world analysis of osimertinib related cardiotoxicity - are we monitoring for this?

Clicks: 1
ID: 323338
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #151 of 282 articles by views in European heart journal supplements : journal of the European Society of Cardiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 282 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Osimertinib is a tyrosine kinase inhibitor used in the treatment of non-small cell lung cancer with an epidermal growth factor receptor (EGFR) mutation. It has been associated with left ventricular systolic dysfunction (LVSD), atrial fibrillation (AF) and QTc prolongation. The European Society of Cardiology (ESC) recommends performing an ECG and transthoracic echocardiogram (TTE) prior to therapy, with consideration of 3-monthly TTEs during treatment and magnesium level monitoring to mitigate the risk of QTc prolongation. Nevertheless, osimertinib remains under-recognised as a cause of cardiotoxicity, resulting in inconsistent cardiac surveillance. Purpose Real world data on osimertinib-related cardiotoxicity has predominantly come from East Asian populations. This study aims to assess this in a diverse European metropolitan population. Secondary aims include evaluating compliance of cardiac surveillance with the 2022 ESC Cardio-oncology guidelines. Methods A retrospective study of all patients treated with osimertinib at a single university hospital cancer centre between October 2023 and September 2025 was performed. Data on baseline characteristics, cardiac investigations, and outcomes was collected. Cancer therapy-related cardiovascular toxicity (CTR-CVT) was defined as per the 2022 ESC Cardio-Oncology guidelines. Results A total of 116 patients received osimertinib during the study period. 79 (68%) were female with a median age of 63 (IQR 56-71) years. Patients represented diverse ethnic backgrounds including 53% White, 12% Black and 8% East Asian. Compliance with ESC guidance was poor (Table 1). Before treatment only 60 (52%) patients had an ECG and 12 (10%) had a TTE performed. During treatment, 62 (53%) had an ECG, 35 (30%) had one TTE, and 13 (11%) had magnesium levels checked. Only 2 patients (2%) underwent post treatment TTE. Twelve (10%) CTR-CVT events occurred (Figure 2) of which 5% were LVSD. Of the six patients with LVSD, two had normal baseline TTEs and met criteria for cancer therapy related cardiac dysfunction (CTRCD). All had elevated NT-proBNP at diagnosis. Four (3%) were hospitalized for cardiovascular (CV) causes and two (2%) CV deaths occurred. Conclusion CTR-CVT events in this diverse cohort were higher than in previous studies (10%). This was likely underestimated due to limited cardiac surveillance, meaning asymptomatic CTRCD was not identified. Compliance with ESC Cardio-Oncology guidelines was low, particularly where only 10% had a baseline echocardiogram performed. These findings suggest that osimertinib may be associated with higher rates of CTR-CVT than previously thought, reinforcing the need for improved monitoring through guideline adherence. This is particularly relevant with the expanding use of osimertinib. In resource constrained healthcare systems, NT pro BNP may be useful to stratify those in need of urgent echocardiography during treatment.Table 1 Figure 1
Reference Key
openalex_W7172255511 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors D M Noakes, N Letteri, D Griffin, C Bannister, A D'silva
Journal European heart journal supplements : journal of the European Society of Cardiology
Year 2026
DOI
10.1093/eurheartjsupp/suag097.042
URL
https://doi.org/10.1093/eurheartjsupp/suag097.042
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.